Tumor necrosis factor alpha protects against lethal West Nile virus infection by promoting trafficking of mononuclear leukocytes into the central nervous system

Journal of Virology

Volumn 82, Issue 18, 2008, Pages 8956-8964

  Shrestha, Bimmi ^a   Zhang, Bo ^a   Purtha, Whitney E ^a   Klein, Robyn S ^a   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IONOMYCIN; NEUTRALIZING ANTIBODY; PHORBOL ESTER; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; B LYMPHOCYTE; BRAIN CELL; C57BL 6 MOUSE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOMODULATION; IN VIVO STUDY; LEUKOCYTE MIGRATION; MACROPHAGE; MONONUCLEAR CELL; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL TIME; VERO CELL; VIRUS ENCEPHALITIS; VIRUS TITRATION; WEST NILE FLAVIVIRUS; WILD TYPE;

ANIMALS; ANTIBODIES, VIRAL; BRAIN; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM; HUMANS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; WEST NILE FEVER; WEST NILE VIRUS;

FLAVIVIRUS; MUS; WEST NILE VIRUS;

EID: 50949117801     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01118-08     Document Type: Article

References (57)

1. Agrawal, A. G., and L. R. Petersen. 2003. Human immunoglobulin as a treatment for West Nile virus infection. J. Infect. Dis. 188:1-4.
2. Atrasheuskaya, A., P. Petzelbauer, T. M. Fredeking, and G. Ignatyev. 2003. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol. Med. Microbiol. 35:33-42.
3. Benedict, C. A. 2003. Viruses and the TNF-related cytokines, an evolving battle. Cytokine Growth Factor Rev. 14:349-357.
4. Benihoud, K., S. Esselin, D. Descamps, B. Jullienne, B. Salone, P. Bobe, D. Bonardelle, E. Connault, P. Opolon, I. Saggio, and M. Perricaudet. 2007. Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice. Gene Ther. 14:533-544.
5. Borrow, P., S. Hou, S. Gloster, M. Ashton, and L. Hyland. 2005. Virus infection-associated bone marrow B cell depletion and impairment of humoral immunity to heterologous infection mediated by TNF-alpha/LTalpha. Eur. J. Immunol. 35:524-532.
6. Bradley, J. R. 2008. TNF-mediated inflammatory disease. J. Pathol. 214:149-160.
7. Brien, J. D., J. L. Uhrlaub, and J. Nikolich-Zugich. 2007. Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection. Eur. J. Immunol. 37:1855-1863.
8. Bromberg, J. S., K. D. Chavin, and S. L. Kunkel. 1992. Anti-tumor necrosis factor antibodies suppress cell-mediated immunity in vivo. J. Immunol. 148:3412-3417.
9. Chan-Tack, K. M., and G. Forrest. 2006. West Nile virus meningoencephalitis and acute flaccid paralysis after infliximab treatment. J. Rheumatol. 33:191-192.
10. Chen, H. C., F. M. Hofman, J. T. Kung, Y. D. Lin, and B. A. Wu-Hsieh. 2007. Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. J. Virol. 81:5518-5526.
11. Cheng, Y., N. J. King, and A. M. Kesson. 2004. The role of tumor necrosis factor in modulating responses of murine embryo fibroblasts by flavivirus, West Nile. Virology 329:361-370.
12. Daffis, S., M. A. Samuel, B. C. Keller, M. Gale, Jr., and M. S. Diamond. 2007. Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and independent mechanisms. PLoS Pathog. 3:e106.
13. Deckert-Schlüter, M., H. Bluethmann, A. Rang, H. Hof, and D. Schluter. 1998. Crucial role of TNF receptor type 1 (p55), but not of TNF receptor type 2 (p75), in murine toxoplasmosis. J. Immunol. 160:3427- 3436.
14. Diamond, M. S. 2005. Development of effective therapies against West Nile virus infection. Expert Rev. Anti-Infect. Ther. 3:931-944.
15. Diamond, M. S., T. Roberts, D. Edgil, B. Lu, J. Ernst, and E. Harris. 2000. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J. Virol. 74:4957-4966.
16. Diamond, M. S., B. Shrestha, A. Marri, D. Mahan, and M. Engle. 2003. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77:2578-2586.
17. Diamond, M. S., E. Sitati, L. Friend, B. Shrestha, S. Higgs, and M. Engle. 2003. A critical role for induced IgM in the protection against West Nile virus infection. J. Exp. Med. 198:1853-1862.
18. Fernández-Mestre, M. T., K. Gendzekhadze, P. Rivas-Vetencourt, and Z. Layrisse. 2004. TNF-alpha-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. Tissue Antigens 64:469-472.
19. Garcia-Tapia, D., D. E. Hassett, W. J. Mitchell, Jr., G. C. Johnson, and S. B. Kleiboeker. 2007. West Nile virus encephalitis: sequential histopathological and immunological events in a murine model of infection. J. Neurovirol. 13:130-138.
20. Glass, W. G., J. K. Lim, R. Cholera, A. G. Pletnev, J. L. Gao, and P. M. Murphy. 2005. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 202:1087-1098.
21. Hall, R. A., and A. A. Khromykh. 2004. West Nile virus vaccines. Expert Opin. Biol. Ther. 4:1295-1305.
22. Herbein, G., and W. A. O'Brien. 2000. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc. Soc. Exp. Biol. Med. 223:241-257.
23. Hickey, M. J., P. H. Reinhardt, L. Ostrovsky, W. M. Jones, M. A. Jutila, D. Payne, J. Elliott, and P. Kubes. 1997. Tumor necrosis factor-alpha induces leukocyte recruitment by different mechanisms in vivo and in vitro. J. Immunol. 158:3391-3400.
24. Hu, H. M., H. Winter, J. Ma, M. Croft, W. J. Urba, and B. A. Fox. 2002. CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells. J. Immunol. 169:4897-4904.
25. Kahn, M. A., J. M. Dopp, S. Liva, A. J. MacKenzie-Graham, R. Chang, A. Huang, R. Nazarian, P. Dell'Albani, D. Condorelli, R. R. Voskuhl, and J. de Vellis. 1999. Temporal kinetics and cellular phenotype of TNF p55/p75 receptors in experimental allergic encephalomyelitis. J. Neuroimmunol. 95:19-34.
26. Keller, B. C., B. L. Fredericksen, M. A. Samuel, R. E. Mock, P. W. Mason, M. S. Diamond, and M. Gale, Jr. 2006. Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J. Virol. 80:9424-9434.
27. + T cell recruitment and control of West Nile virus encephalitis. J. Virol. 79:11457-11466.
28. Lundberg, P., P. V. Welander, C. K. Edwards III, N. van Rooijen, and E. Cantin. 2007. Tumor necrosis factor (TNF) protects resistant C57BL/6 mice against herpes simplex virus-induced encephalitis independently of signaling via TNF receptor 1 or 2. J. Virol. 81:1451-1460.
29. Monath, T. P., J. Liu, N. Kanesa-Thasan, G. A. Myers, R. Nichols, A. Deary, K. McCarthy, C. Johnson, T. Ermak, S. Shin, J. Arroyo, F. Guirakhoo, J. S. Kennedy, F. A. Ennis, S. Green, and P. Bedford. 2006. A live, attenuated recombinant West Nile virus vaccine. Proc. Natl. Acad. Sci. USA 103:6694-6699.
30. Norman, M. U., K. J. Lister, Y. H. Yang, A. Issekutz, and M. J. Hickey. 2005. TNF regulates leukocyte-endothelial cell interactions and microvascular dysfunction during immune complex-mediated inflammation. Br. J. Pharmacol. 144:265-274.
31. Pasparakis, M., L. Alexopoulou, V. Episkopou, and G. Kollias. 1996. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184:1397-1411.
32. Pasparakis, M., L. Alexopoulou, M. Grell, K. Pfizenmaier, H. Bluethmann, and G. Kollias. 1997. Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor. Proc. Natl. Acad. Sci. USA 94:6319-6323.
33. Peschon, J. J., D. S. Torrance, K. L. Stocking, M. B. Glaccum, C. Otten, C. R. Willis, K. Charrier, P. J. Morrissey, C. B. Ware, and K. M. Mohler. 1998. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. 160:943-952.
34. Purtha, W. E., N. Myers, V. Mitaksov, E. Sitati, J. Connolly, D. H. Fremont, T. H. Hansen, and M. S. Diamond. 2007. Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. Eur. J. Immunol. 37:1845-1854.
35. Roach, D. R., A. G. Bean, C. Demangel, M. P. France, H. Briscoe, and W. J. Britton. 2002. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol. 168:4620-4627.
36. Rossol-Voth, R., S. Rossol, K. H. Schutt, S. Corridori, W. de Cian, and D. Falke. 1991. In vivo protective effect of tumour necrosis factor alpha against experimental infection with herpes simplex virus type 1. J. Gen. Virol. 72:143-147.
37. Ruby, J., H. Bluethmann, and J. J. Peschon. 1997. Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors. J. Exp. Med. 186:1591-1596.
38. Samuel, M. A., and M. S. Diamond. 2006. Pathogenesis of West Nile virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J. Virol. 80:9349-9360.
39. Samuel, M. A., and M. S. Diamond. 2005. Type 1 IFN protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 79:13350-13361.
40. Samuel, M. A., K. Whitby, B. C. Keller, A. Marri, W. Barchet, B. R. G. Williams, R. H. Silverman, M. Gale, and M. S. Diamond. 2006. PKR and RNase L contribute to protection against lethal West Nile virus infection by controlling early viral spread in the periphery and replication in neurons. J. Virol. 80:7009-7019.
41. Sedgwick, J. D., D. S. Riminton, J. G. Cyster, and H. Korner. 2000. Tumor necrosis factor: a master-regulator of leukocyte movement. Immunol. Today 21:110-113.
42. Sejvar, J. J., A. V. Bode, A. A. Marfin, G. L. Campbell, J. Pape, B. J. Biggerstaff, and L. R. Petersen. 2006. West Nile virus-associated flaccid paralysis outcome. Emerg. Infect. Dis. 12:514-516.
43. Sejvar, J. J., M. B. Haddad, B. C. Tierney, G. L. Campbell, A. A. Marfin, J. A. Van Gerpen, A. Fleischauer, A. A. Leis, D. S. Stokic, and L. R. Petersen. 2003. Neurologic manifestations and outcome of West Nile virus infection. JAMA 290:511-515.
44. Shen, J., S. S. T-To, L. Schrieber, and N. J. King. 1997. Early E-selectin, VCAM-1, ICAM-1, and late major histocompatibility complex antigen induction on human endothelial cells by flavivirus and comodulation of adhesion molecule expression by immune cytokines. J. Virol. 71:9323-9332.
45. Shresta, S., K. L. Sharar, D. M. Prigozhin, P. R. Beatty, and E. Harris. 2006. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80:10208-10217.
46. + T-cell-mediated control of West Nile virus infection in the central nervous system. J. Virol. 81:11749-11757.
47. Shrestha, B., and M. S. Diamond. 2004. The role of CD8+ T cells in the control of West Nile virus infection. J. Virol. 78:8312-8321.
48. Shrestha, B., D. I. Gottlieb, and M. S. Diamond. 2003. Infection and injury of neurons by West Nile encephalitis virus. J. Virol. 77:13203-13213.
49. + T cells require perforin to clear West Nile virus from infected neurons. J. Virol. 80:119-129.
50. Shrestha, B., T. Wang, M. A. Samuel, K. Whitby, J. Craft, E. Fikrig, and M. S. Diamond. 2006. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J. Virol. 80:5338-5348.
51. + T cells into the brain and protection against West Nile virus encephalitis. J. Virol. 81:9801-9811.
52. Suresh, M., X. Gao, C. Fischer, N. E. Miller, and K. Tewari. 2004. Dissection of antiviral and immune regulatory functions of tumor necrosis factor receptors in a chronic lymphocytic choriomeningitis virus infection. J. Virol. 78:3906-3918.
53. Wang, T., T. Town, L. Alexopoulou, J. F. Anderson, E. Fikrig, and R. A. Flavell. 2004. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 10:1366-1373.
54. + T cells mediate recovery and immunopathology in West Nile virus encephalitis. J. Virol. 77:13323-13334.
55. Wati, S., P. Li, C. J. Burrell, and J. M. Carr. 2007. Dengue virus (DV) replication in monocyte-derived macrophages is not affected by tumor necrosis factor alpha (TNF-alpha), and DV infection induces altered responsiveness to TNF-alpha stimulation. J. Virol. 81:10161-10171.
56. Willenborg, D. O., R. D. Simmons, T. Tamatani, and M. Miyasaka. 1993. ICAM-1-dependent pathway is not critically involved in the inflammatory process of autoimmune encephalomyelitis or in cytokine-induced inflammation of the central nervous system. J. Neuroimmunol. 45:147-154.
57. Zhang, B., Y. K. Chan, B. Lu, M. S. Diamond, and R. S. Klein. 2008. CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. J. Immunol. 180:2641-2649.